Penta-NASHNAFLD Platform for Non-Alcoholic Steatohepatitis and Fatty Liver Disease
Disease Background: Non-Alcoholic Steatohepatitis (NASH) and Fatty Liver Disease (NAFLD) is characterized with liver inflammation and injury due to a buildup of fat in the liver. A continued buildup of fat leads to scarring of the liver, also called fibrosis. As fibrosis spreads to occupy a major portion of the liver, the liver turns cirrhotic with associated ascites, swelling of veins and liver cancer leading to end stage liver failure. Patients with obesity, insulin resistance, hyperglycemia and high blood triglycerides are at higher risk of developing NASH and NAFLD.
Details on the Model: Pentagrit Zebrafish NASH and NAFLD model employs high fat diet to developed obese fish. The obese fish progresses to a NASH pathogenesis characterized by accumulation of fat, visceral adiposity with associated insulin resistance and glucose intolerance, elevated systemic high cholesterol and high triglycerides. A continued obese diet to NASH fish leads to a cirrhotic liver with end stage liver failure. Saroglitazar rescues liver inflammation, delays fat accumulation with decreased mortality in treated fish groups compared to placebo fed zebrafish groups.